Apolipoprotein B100 quality control and the regulation of hepatic very low density lipoprotein secretion
Apolipoprotein B (apoB) is the main protein component of very low density lipoprotein (VLDL) and is necessary for the assembly and secretion of these triglyceride (TG)-rich particles. Following release from the liver, VLDL is converted to low density lipoprotein (LDL) in the plasma and increased pro...
Saved in:
Published in | Journal of biomedical research Vol. 28; no. 3; pp. 178 - 193 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
China
Editorial Department of Journal of Biomedical Research
01.01.2014
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Apolipoprotein B (apoB) is the main protein component of very low density lipoprotein (VLDL) and is necessary for the assembly and secretion of these triglyceride (TG)-rich particles. Following release from the liver, VLDL is converted to low density lipoprotein (LDL) in the plasma and increased production of VLDL can therefore play a detrimental role in cardiovascular disease. Increasing evidence has helped to establish VLDL assembly as a target for the treatment of dyslipidemias. Multiple factors are involved in the folding of the apoB protein and the formation of a secretion-competent VLDL particle. Failed VLDL assembly can initiate quality control mechanisms in the hepatocyte that target apoB for degradation. ApoB is a substrate for endoplasmic reticulum associated degradation (ERAD) by the ubiquitin proteasome system and for autophagy. Efficient targeting and disposal of apoB is a regu- lated process that modulates VLDL secretion and partitioning of TG. Emerging evidence suggests that significant overlap exists between these degradative pathways. For example, the insulin-mediated targeting of apoB to autop- hagy and postprandial activation of the unfolded protein response (UPR) may employ the same cellular machinery and regulatory cues. Changes in the quality control mechanisms for apoB impact hepatic physiology and pathology states, including insulin resistance and fatty liver. Insulin signaling, lipid metabolism and the hepatic UPR may impact VLDL production, particularly during the postprandial state. In this review we summarize our current understanding of VLDL assembly, apoB degradation, quality control mechanisms and the role of these processes in liver physiology and in pathologic states. |
---|---|
AbstractList | Apolipoprotein B (apoB) is the main protein component of very low density lipoprotein (VLDL) and is necessary for the assembly and secretion of these triglyceride (TG)-rich particles. Following release from the liver, VLDL is converted to low density lipoprotein (LDL) in the plasma and increased production of VLDL can therefore play a detrimental role in cardiovascular disease. Increasing evidence has helped to establish VLDL assembly as a target for the treatment of dyslipidemias. Multiple factors are involved in the folding of the apoB protein and the formation of a secretion-competent VLDL particle. Failed VLDL assembly can initiate quality control mechanisms in the hepatocyte that target apoB for degradation. ApoB is a substrate for endoplasmic reticulum associated degradation (ERAD) by the ubiquitin proteasome system and for autophagy. Efficient targeting and disposal of apoB is a regulated process that modulates VLDL secretion and partitioning of TG. Emerging evidence suggests that significant overlap exists between these degradative pathways. For example, the insulin-mediated targeting of apoB to autophagy and postprandial activation of the unfolded protein response (UPR) may employ the same cellular machinery and regulatory cues. Changes in the quality control mechanisms for apoB impact hepatic physiology and pathology states, including insulin resistance and fatty liver. Insulin signaling, lipid metabolism and the hepatic UPR may impact VLDL production, particularly during the postprandial state. In this review we summarize our current understanding of VLDL assembly, apoB degradation, quality control mechanisms and the role of these processes in liver physiology and in pathologic states. Apolipoprotein B (apoB) is the main protein component of very low density lipoprotein (VLDL) and is necessary for the assembly and secretion of these triglyceride (TG)-rich particles. Following release from the liver, VLDL is converted to low density lipoprotein (LDL) in the plasma and increased production of VLDL can therefore play a detrimental role in cardiovascular disease. Increasing evidence has helped to establish VLDL assembly as a target for the treatment of dyslipidemias. Multiple factors are involved in the folding of the apoB protein and the formation of a secretion-competent VLDL particle. Failed VLDL assembly can initiate quality control mechanisms in the hepatocyte that target apoB for degradation. ApoB is a substrate for endoplasmic reticulum associated degradation (ERAD) by the ubiquitin proteasome system and for autophagy. Efficient targeting and disposal of apoB is a regu- lated process that modulates VLDL secretion and partitioning of TG. Emerging evidence suggests that significant overlap exists between these degradative pathways. For example, the insulin-mediated targeting of apoB to autop- hagy and postprandial activation of the unfolded protein response (UPR) may employ the same cellular machinery and regulatory cues. Changes in the quality control mechanisms for apoB impact hepatic physiology and pathology states, including insulin resistance and fatty liver. Insulin signaling, lipid metabolism and the hepatic UPR may impact VLDL production, particularly during the postprandial state. In this review we summarize our current understanding of VLDL assembly, apoB degradation, quality control mechanisms and the role of these processes in liver physiology and in pathologic states. |
Author | Eric Fisher Elizabeth Lake Roger S McLeod |
AuthorAffiliation | Biochemistry & Molecular Biology, Faculty of Medicine, Dalhousie University, Halifax, NS B3H 4R2, Canada. |
AuthorAffiliation_xml | – name: Biochemistry & Molecular Biology, Faculty of Medicine, Dalhousie University, Halifax, NS B3H 4R2, Canada |
Author_xml | – sequence: 1 givenname: Eric surname: Fisher fullname: Fisher, Eric organization: Biochemistry & Molecular Biology, Faculty of Medicine, Dalhousie University, Halifax, NS B3H 4R2, Canada – sequence: 2 givenname: Elizabeth surname: Lake fullname: Lake, Elizabeth organization: Biochemistry & Molecular Biology, Faculty of Medicine, Dalhousie University, Halifax, NS B3H 4R2, Canada – sequence: 3 givenname: Roger S surname: McLeod fullname: McLeod, Roger S organization: Biochemistry & Molecular Biology, Faculty of Medicine, Dalhousie University, Halifax, NS B3H 4R2, Canada |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25013401$$D View this record in MEDLINE/PubMed |
BookMark | eNpVkcFPHCEUxjnYqLWevTV487IrzMDAXJqoadXGxKSpZ8Iyjx0MC7Mws83-92XjulEuQN73_XiP7ys6CjEAQheUzAXn_Pp1keaVnFeEMkJoe4ROaSPYTNaEnqDznF9JWXXbVEweo5OKE1ozQk9RfzNE74Y4pDiCC_iWEoLXk_Zu3GITw5iixzp0eOwBJ1hOXo8uBhwt7mEoZ4M3kLbYx3-4g5B3to-8DCbBzvENfbHaZzjf72fo5dfPv3cPs6fn-8e7m6eZYZKPs5YY2zSadqxqW20t59BR0YEmWnIrgNSWL8QChOia1ggpDdWtoOUiq4ZZWp-hH2_cYVqsoDNQRtBeDcmtdNqqqJ36XAmuV8u4UYzI8pG8AK72gBTXE-RRrVw24L0OEKesKGdMlO4EKdLrN6lJMecE9vAMJWoXi_p9-0dVUr3HUhzfP3Z30L8HUgSXe2Qfw3LtwvKg4aSmsm5E_R9t95pD |
CitedBy_id | crossref_primary_10_2174_1389557523666230314113543 crossref_primary_10_1016_j_dld_2016_03_016 crossref_primary_10_1016_j_toxlet_2017_09_005 crossref_primary_10_1016_j_envpol_2023_122894 crossref_primary_10_3390_ijms18122717 crossref_primary_10_1016_j_jacl_2017_06_013 crossref_primary_10_1016_j_bbalip_2016_01_014 crossref_primary_10_1007_s10565_020_09537_1 crossref_primary_10_3389_fvets_2023_1192841 crossref_primary_10_1089_dna_2017_3853 crossref_primary_10_1371_journal_pgen_1009357 crossref_primary_10_1080_08927022_2016_1149701 crossref_primary_10_3390_antiox9100980 crossref_primary_10_1016_j_jacl_2020_12_010 crossref_primary_10_1038_ncomms12848 crossref_primary_10_3390_nu16010025 crossref_primary_10_1002_hep_30411 crossref_primary_10_1016_j_jacl_2015_01_005 crossref_primary_10_1021_acs_jproteome_0c00235 crossref_primary_10_2174_1568026620666200325112425 crossref_primary_10_3390_ijms18071552 crossref_primary_10_1007_s00268_017_4281_3 crossref_primary_10_1038_s41467_024_46102_4 crossref_primary_10_1007_s13340_023_00675_5 crossref_primary_10_1152_ajpendo_00276_2019 crossref_primary_10_1371_journal_ppat_1009889 crossref_primary_10_1080_15548627_2015_1127464 crossref_primary_10_1074_jbc_M115_645200 crossref_primary_10_1093_cvr_cvae121 crossref_primary_10_1002_jcb_25860 crossref_primary_10_1038_s41467_019_11259_w crossref_primary_10_1091_mbc_E17_08_0514 crossref_primary_10_1016_j_phrs_2020_104840 crossref_primary_10_1194_jlr_RA120000888 |
ContentType | Journal Article |
Copyright | 2014 the Journal of Biomedical Research. All rights reserved. 2014 |
Copyright_xml | – notice: 2014 the Journal of Biomedical Research. All rights reserved. 2014 |
DBID | 2RA 92L CQIGP W91 ~WA NPM AAYXX CITATION 7X8 5PM |
DOI | 10.7555/jbr.28.20140019 |
DatabaseName | 维普_期刊 中文科技期刊数据库-CALIS站点 中文科技期刊数据库-7.0平台 中文科技期刊数据库-医药卫生 中文科技期刊数据库- 镜像站点 PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | Apolipoprotein B100 quality control and the regulation of hepatic very low density lipoprotein secretion ApoB quality control and regulation of VLDL secretion |
EndPage | 193 |
ExternalDocumentID | 10_7555_JBR_28_20140019 25013401 50318367 |
Genre | Journal Article |
GroupedDBID | --- --K .~1 0R~ 1B1 1~. 1~5 2B. 2C~ 2RA 4.4 457 4G. 5VR 5VS 7-5 71M 92F 92I 92L 93N 93R AAEDT AALRI AAQFI AAXUO ABBQC ABDBF ABYKQ ADRAZ AEGXH AEKER AFUIB AGYEJ AITUG AJBFU AJRQY ALMA_UNASSIGNED_HOLDINGS AMFUW CCEZO CHBEP CIEJG CQIGP CW9 DIK EBD EBS EJD EOJEC FA0 FDB FEDTE FNPLU GBLVA GX1 HVGLF HYE HZ~ J1W KQ8 M41 M48 MO0 N9A O-L O9- OBODZ OK1 OZT P-8 P-9 P6G PC. Q38 RIG RNS ROL RPM SDF SES TCJ TGQ TUS W91 WFFXF ~WA -SE -S~ AAXDM CAJEE NPM Q-- U1G U5O AAYXX CITATION 7X8 5PM |
ID | FETCH-LOGICAL-c485t-90cf66a1d4299aff55ed17dea0a85f7e03f5b7be77d69c788c1a971d698264f13 |
IEDL.DBID | RPM |
ISSN | 1674-8301 |
IngestDate | Tue Sep 17 21:20:04 EDT 2024 Sat Aug 17 02:05:55 EDT 2024 Fri Nov 22 00:26:52 EST 2024 Tue Oct 15 23:54:07 EDT 2024 Wed Feb 14 10:35:24 EST 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | proteasome very low density lipoprotein autophagy apolipoprotein B steatosis ubiquitin |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c485t-90cf66a1d4299aff55ed17dea0a85f7e03f5b7be77d69c788c1a971d698264f13 |
Notes | apolipoprotein B, very low density lipoprotein, proteasome, ubiquitin, autophagy, steatosis 32-1810/R Apolipoprotein B (apoB) is the main protein component of very low density lipoprotein (VLDL) and is necessary for the assembly and secretion of these triglyceride (TG)-rich particles. Following release from the liver, VLDL is converted to low density lipoprotein (LDL) in the plasma and increased production of VLDL can therefore play a detrimental role in cardiovascular disease. Increasing evidence has helped to establish VLDL assembly as a target for the treatment of dyslipidemias. Multiple factors are involved in the folding of the apoB protein and the formation of a secretion-competent VLDL particle. Failed VLDL assembly can initiate quality control mechanisms in the hepatocyte that target apoB for degradation. ApoB is a substrate for endoplasmic reticulum associated degradation (ERAD) by the ubiquitin proteasome system and for autophagy. Efficient targeting and disposal of apoB is a regu- lated process that modulates VLDL secretion and partitioning of TG. Emerging evidence suggests that significant overlap exists between these degradative pathways. For example, the insulin-mediated targeting of apoB to autop- hagy and postprandial activation of the unfolded protein response (UPR) may employ the same cellular machinery and regulatory cues. Changes in the quality control mechanisms for apoB impact hepatic physiology and pathology states, including insulin resistance and fatty liver. Insulin signaling, lipid metabolism and the hepatic UPR may impact VLDL production, particularly during the postprandial state. In this review we summarize our current understanding of VLDL assembly, apoB degradation, quality control mechanisms and the role of these processes in liver physiology and in pathologic states. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 The authors reported no conflict of interests. |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4085555/ |
PMID | 25013401 |
PQID | 1544742970 |
PQPubID | 23479 |
PageCount | 16 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4085555 proquest_miscellaneous_1544742970 crossref_primary_10_7555_JBR_28_20140019 pubmed_primary_25013401 chongqing_primary_50318367 |
PublicationCentury | 2000 |
PublicationDate | 2014-01-01 |
PublicationDateYYYYMMDD | 2014-01-01 |
PublicationDate_xml | – month: 01 year: 2014 text: 2014-01-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | China |
PublicationPlace_xml | – name: China |
PublicationTitle | Journal of biomedical research |
PublicationTitleAlternate | Journal of Biomedical Research |
PublicationYear | 2014 |
Publisher | Editorial Department of Journal of Biomedical Research |
Publisher_xml | – name: Editorial Department of Journal of Biomedical Research |
References | 16620782 - Biochem Biophys Res Commun. 2006 Jun 2;344(2):478-83 17709744 - Proc Natl Acad Sci U S A. 2007 Aug 28;104(35):14056-61 20037162 - J Biol Chem. 2010 Feb 26;285(9):6801-10 8662886 - J Biol Chem. 1996 Jun 14;271(24):14124-33 22517365 - Arterioscler Thromb Vasc Biol. 2012 May;32(5):1073-8 21857022 - J Biol Chem. 2011 Oct 28;286(43):37602-14 9565615 - J Biol Chem. 1998 May 8;273(19):11887-94 18804479 - J Mol Biol. 2008 Nov 28;383(5):1181-94 20816088 - Cell Metab. 2010 Sep 8;12(3):213-23 22751103 - J Clin Invest. 2012 Aug;122(8):2807-16 177430 - J Cell Biol. 1976 May;69(2):241-63 9065474 - J Biol Chem. 1997 Mar 21;272(12):8019-25 10477822 - Biochim Biophys Acta. 1999 Aug 25;1440(1):1-31 10811609 - EMBO J. 2000 May 15;19(10):2181-92 21547407 - Eur J Nutr. 2011 Jun;50(4):219-33 1464582 - J Biol Chem. 1992 Dec 25;267(36):25621-4 15215855 - Nature. 2004 Jun 24;429(6994):834-40 15096051 - Biochemistry. 2004 Apr 27;43(16):4819-31 7929292 - J Biol Chem. 1994 Oct 14;269(41):25879-88 21447637 - Endocrinology. 2011 Jun;152(6):2247-55 9857060 - J Biol Chem. 1998 Dec 25;273(52):35216-21 19723664 - J Lipid Res. 2010 Mar;51(3):544-53 20130085 - Mol Biol Cell. 2010 Apr 1;21(7):1305-13 22701043 - J Lipid Res. 2012 Sep;53(9):1800-10 15177262 - Trends Cardiovasc Med. 2004 May;14(4):127-32 22448156 - Metabolomics. 2012 Apr;8(2):347-359 24005219 - Curr Opin Lipidol. 2013 Oct;24(5):450-2 19394298 - Mol Cell. 2009 Apr 24;34(2):212-22 12837846 - J Lipid Res. 2003 Oct;44(10):1841-9 22796579 - Arterioscler Thromb Vasc Biol. 2012 Sep;32(9):2104-12 8052632 - Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7628-32 19622837 - J Lipid Res. 2010 Jan;51(1):150-61 22271167 - Hepatology. 2012 Jul;56(1):270-80 20406816 - J Biol Chem. 2010 Jun 18;285(25):19288-98 16396637 - Biochem J. 2006 Apr 15;395(2):363-71 15157107 - Biochemistry. 2004 Jun 1;43(21):6734-44 21220515 - Mol Cell Biol. 2011 Mar;31(6):1145-59 21430026 - J Clin Endocrinol Metab. 2011 Jul;96(7):2163-70 8429031 - J Biol Chem. 1993 Feb 15;268(5):3555-62 20395947 - Obesity (Silver Spring). 2010 Aug;18(8):1510-5 22121032 - Hepatology. 2012 May;55(5):1356-68 19592617 - Diabetes. 2009 Oct;58(10):2198-210 19363290 - J Clin Invest. 2009 May;119(5):1201-15 10583943 - Science. 1999 Dec 3;286(5446):1882-8 22661308 - J Lipid Res. 2012 Sep;53(9):1877-89 16822850 - Hum Mol Genet. 2006 Aug 15;15(16):2409-20 19211039 - Biochim Biophys Acta. 2009 Mar;1791(3):198-205 16672736 - J Lipid Res. 2006 Aug;47(8):1749-61 22238364 - Mol Biol Cell. 2012 Mar;23(5):800-10 8702489 - J Biol Chem. 1996 Aug 2;271(31):18445-55 10064309 - J Nutr. 1999 Feb;129(2S Suppl):456S-462S 12072432 - J Biol Chem. 2002 Aug 30;277(35):31516-25 21550083 - Metabolism. 2011 Oct;60(10):1482-7 17521290 - Biochem J. 2007 Jun 15;404(3):353-63 21909096 - Nat Struct Mol Biol. 2011 Sep 11;18(10):1147-52 17170368 - Arterioscler Thromb Vasc Biol. 2007 Mar;27(3):661-70 9252352 - J Biol Chem. 1997 Aug 15;272(33):20435-42 23274236 - Biochim Biophys Acta. 2013 Apr;1831(4):819-24 16854991 - J Biol Chem. 2006 Sep 15;281(37):27063-71 15891394 - Curr Opin Lipidol. 2005 Jun;16(3):325-32 21270237 - Diabetes. 2011 Mar;60(3):918-24 22977624 - Exp Ther Med. 2011 Nov;2(6):1077-1081 21316344 - Biochem Biophys Res Commun. 2011 Mar 11;406(2):252-6 19468685 - Cell Mol Life Sci. 2009 Sep;66(17):2835-50 9252351 - J Biol Chem. 1997 Aug 15;272(33):20427-34 12006608 - J Biol Chem. 2002 May 17;277(20):17377-80 17038630 - Arterioscler Thromb Vasc Biol. 2007 Jan;27(1):211-8 22560215 - Cell Metab. 2012 May 2;15(5):623-34 19626045 - Nat Rev Mol Cell Biol. 2009 Aug;10(8):550-63 10856714 - Biochim Biophys Acta. 2000 Jun 26;1486(1):72-83 11839763 - J Biol Chem. 2002 Apr 19;277(16):14135-45 19922416 - Clin Sci (Lond). 2009 Nov 23;118(5):333-9 24068323 - Mol Biol Cell. 2013 Nov;24(22):3545-56 9139669 - J Biol Chem. 1997 May 9;272(19):12272-8 18550891 - J Lipid Res. 2008 Oct;49(10 ):2149-60 19164805 - Arterioscler Thromb Vasc Biol. 2009 Apr;29(4):579-85 19434737 - Hepatology. 2009 Jul;50(1):77-84 21074049 - Cell. 2010 Nov 12;143(4):579-91 20173742 - Nat Cell Biol. 2010 Mar;12 (3):213-23 9106493 - Biochim Biophys Acta. 1997 Apr 1;1345(2):136-50 20674862 - Cell Metab. 2010 Aug 4;12(2):174-86 21693689 - Am J Physiol Endocrinol Metab. 2011 Sep;301(3):E429-46 24257748 - J Biol Chem. 2014 Jan 3;289(1):1-12 20956548 - J Lipid Res. 2011 Jan;52(1):152-8 20451687 - Am J Cardiol. 2010 May 15;105(10):1413-9 19026012 - Hepatology. 2008 Dec;48(6):1799-809 17288985 - Arch Biochem Biophys. 2007 Mar 1;459(1):10-9 17500069 - J Biol Chem. 2007 Jul 6;282(27):19453-62 22841931 - Pharmacol Res. 2012 Dec;66(6):457-62 23827315 - Arch Biochem Biophys. 2013 Sep 1;537(1):104-12 22854296 - Curr Opin Cell Biol. 2012 Aug;24(4):460-6 14581578 - J Lipid Res. 2004 Feb;45(2):366-77 23685141 - Biochem Biophys Res Commun. 2013 Jun 14;435(4):616-20 15486461 - Rev Endocr Metab Disord. 2004 Dec;5(4):293-301 21421992 - J Lipid Res. 2011 Jun;52(6):1170-80 18669885 - Arterioscler Thromb Vasc Biol. 2008 Oct;28(10):1738-44 20519119 - Cell Metab. 2010 Jun 9;11(6):467-78 23516411 - PLoS One. 2013;8(3):e57590 23485362 - Trends Pharmacol Sci. 2013 Apr;34(4):198-205 8702523 - J Biol Chem. 1996 Aug 2;271(31):18686-94 8901527 - Biochemistry. 1996 Oct 29;35(43):13843-8 11704664 - J Biol Chem. 2002 Feb 8;277(6):4413-21 11714859 - J Lipid Res. 2001 Nov;42(11):1897-904 22371371 - Cold Spring Harb Symp Quant Biol. 2011;76:91-9 22155452 - Arterioscler Thromb Vasc Biol. 2012 Feb;32(2):236-46 16923392 - Cell. 2006 Aug 25;126(4):727-39 18587069 - J Lipid Res. 2008 Oct;49(10):2218-29 11022045 - J Biol Chem. 2001 Jan 5;276(1):541-50 22580899 - Arterioscler Thromb Vasc Biol. 2012 Jul;32(7):1585-95 22326225 - Cell Metab. 2012 Feb 8;15(2):240-6 9694898 - J Biol Chem. 1998 Aug 14;273(33):21368-73 17090753 - Am J Physiol Endocrinol Metab. 2007 Mar;292(3):E732-9 21721546 - Biochemistry. 2011 Aug 16;50(32):6942-50 9278400 - J Biol Chem. 1997 Sep 5;272(36):22489-94 12620753 - Lancet. 2003 Mar 1;361(9359):777-80 20347046 - Semin Cell Dev Biol. 2010 Jul;21(5):500-11 22355095 - J Lipid Res. 2012 May;53(5):859-67 21930939 - Proc Natl Acad Sci U S A. 2011 Sep 27;108(39):16381-5 21889406 - Trends Mol Med. 2012 Jan;18(1):59-68 1848237 - J Biol Chem. 1991 Mar 15;266(8):5080-6 24292014 - Nat Cell Biol. 2014 Jan;16(1):77-86 7559659 - J Biol Chem. 1995 Oct 20;270(42):25220-4 22059644 - Nutr J. 2011 Nov 07;10:122 15538359 - Nature. 2004 Nov 11;432(7014):173-8 20452521 - Lancet. 2010 May 8;375(9726):1634-9 17588943 - J Biol Chem. 2007 Aug 17;282(33):24270-83 18519977 - J Lipid Res. 2008 Sep;49(9):2013-22 15124019 - J Clin Invest. 2004 May;113(9):1277-87 21124217 - Curr Opin Lipidol. 2011 Apr;22(2):79-85 19383982 - J Lipid Res. 2009 Sep;50(9):1814-23 21486563 - FEBS Lett. 2011 May 6;585(9):1281-6 23376223 - Biochim Biophys Acta. 2013 Jun;1831(6):1113-23 18391222 - Proc Natl Acad Sci U S A. 2008 Apr 15;105(15):5862-7 23870665 - Trends Biochem Sci. 2013 Sep;38(9):453-60 19546513 - Gerontology. 2009;55(5):550-8 22806626 - Hepatology. 2012 Dec;56(6):2188-98 16550215 - Nat Rev Mol Cell Biol. 2006 May;7(5):373-8 23890821 - Cell. 2013 Aug 1;154(3):609-22 8071315 - J Biol Chem. 1994 Sep 2;269(35):21951-4 18577578 - J Cell Sci. 2008 Jul 15;121(Pt 14):2415-22 20215580 - J Lipid Res. 2010 Apr;51(4):729-42 9843958 - Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14733-8 3680257 - J Biol Chem. 1987 Dec 5;262(34):16394-402 22466652 - J Clin Invest. 2012 May;122(5):1677-87 18502767 - J Biol Chem. 2008 Jul 18;283(29):19967-80 24206663 - Cell Metab. 2013 Nov 5;18(5):685-97 19342510 - Am J Physiol Gastrointest Liver Physiol. 2009 Jun;296(6):G1287-98 20227758 - Lancet. 2010 Mar 20;375(9719):998-1006 21793029 - Hepatology. 2011 Nov;54(5):1650-60 16156669 - Biochemistry. 2005 Sep 20;44(37):12572-81 15952902 - Annu Rev Biochem. 2005;74:739-89 20189175 - Atherosclerosis. 2010 Aug;211(2):353-60 22594799 - Arch Physiol Biochem. 2012 Jul;118(3):102-11 22592119 - Arterioscler Thromb Vasc Biol. 2012 Jun;32(6):1334-8 19615732 - Cell. 2009 Jul 23;138(2):389-403 21360721 - Hepatology. 2011 May;53(5):1515-25 19251580 - J Lipid Res. 2009 Jul;50(7):1340-52 8485114 - Arterioscler Thromb. 1993 May;13(5):629-36 11333259 - J Biol Chem. 2001 Jul 6;276(27):24891-900 22257482 - J Lipid Res. 2012 Apr;53(4):736-43 10722675 - J Biol Chem. 2000 Mar 24;275(12):8416-25 20357000 - Mol Biol Cell. 2010 May 15;21(10):1662-70 20237065 - J Nutr. 2010 May;140(5):879-84 22590560 - PLoS One. 2012;7(5):e36542 19818707 - Mol Cell. 2009 Oct 9;36(1):28-38 16679290 - Cell Metab. 2006 May;3(5):321-31 7846033 - Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):659-63 14970200 - J Biol Chem. 2004 Apr 30;279(18):19362-74 10922368 - J Biol Chem. 2000 Oct 13;275(41):32003-10 11485165 - Lipids. 2001 Jun;36(6):607-12 23123764 - Curr Opin Lipidol. 2013 Apr;24(2):160-70 19497957 - Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G323-32 23800989 - Cell Mol Life Sci. 2013 Dec;70(24):4681-94 22633958 - Mol Cell. 2012 Jun 29;46(6):809-19 16979555 - Curr Biol. 2006 Sep 19;16(18):1783-95 15716585 - J Lipid Res. 2005 May;46(5):872-84 19501581 - Clin Biochem. 2009 Sep;42(13-14):1331-46 12454278 - J Lipid Res. 2002 Dec;43(12):2155-63 17650499 - J Biol Chem. 2007 Sep 14;282(37):26845-56 16873066 - Cell. 2006 Jul 28;126(2):361-73 8576187 - J Biol Chem. 1996 Feb 2;271(5):2353-6 20421882 - Nat Rev Endocrinol. 2010 Jun;6(6):335-46 21532591 - Nature. 2011 May 26;473(7348):528-31 23257357 - J Clin Invest. 2013 Jan;123(1):455-68 24136824 - J Lipid Res. 2014 Jan;55(1):75-84 17565364 - Nat Rev Mol Cell Biol. 2007 Jul;8(7):519-29 22883813 - Trends Mol Med. 2012 Oct;18(10):589-98 20303879 - Cell. 2010 Mar 19;140(6):900-17 22517367 - Arterioscler Thromb Vasc Biol. 2012 May;32(5):1087-93 21636303 - Mol Cell. 2011 Jun 24;42(6):758-70 22116877 - Science. 2011 Nov 25;334(6059):1081-6 24424410 - Elife. 2014;3:e01369 23338832 - Cell Mol Life Sci. 2013 Jun;70(11):1985-2002 16597703 - Mol Biol Cell. 2006 Jun;17(6):2674-83 20670887 - Mol Cell. 2010 Jul 30;39(2):171-83 20005842 - Mol Cell. 2009 Dec 11;36(5):782-93 20513765 - J Cell Biol. 2010 May 31;189(5):783-94 21836065 - Arterioscler Thromb Vasc Biol. 2011 Nov;31(11):2692-9 22342675 - Biochim Biop |
References_xml | |
SSID | ssj0000396248 |
Score | 2.1986794 |
Snippet | Apolipoprotein B (apoB) is the main protein component of very low density lipoprotein (VLDL) and is necessary for the assembly and secretion of these... Apolipoprotein B (apoB) is the main protein component of very low density lipoprotein (VLDL) and is necessary for the assembly and secretion of these... |
SourceID | pubmedcentral proquest crossref pubmed chongqing |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 178 |
SubjectTerms | Invited Review VLDL 极低密度脂蛋白 肝脏 胰岛素抵抗 蛋白分泌 质量控制机制 载脂蛋白B100 降解途径 |
SummonAdditionalLinks | – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1LT8MwDI5gSMAF8WbjoSBx4NLRV5LmhACB0KRxQEziVqVNwoamdmxDsH-P3XZj49Fb1caNYif-3DifCTlT2tWRZqHDZRI4oQm5k2gbOTxJbepihZHihFz7gd93wtYze_4uB1QN4OjP0A7rSXWG_ebn2-QSJjzg16ZgjF28JsOmX6RphYhYlsmKD24R87vaFdYvluVAcr-opoWJ904Ell1S_fwlAzmCGaCjEIvFrEFfspc3cCWLzusXIv2ZWDnnqe42yUYFMelVaRNbZMlk22S1XW2i75DuFVZmGOQFRUMvo9ee69LycOWEVqnrVGWaAjakw7JWPWiP5pZ2DSZgpxTsf0L7-QfVmP8OzebljRCJYotd0rm7fbq5d6qCC04aRmzsSDe1nCtPo5NS1jJmtCe0Ua6KmBXGDSxLRGKE0FymEDynnpLCgxsIUkLrBXukluWZOSAUeUolE8oXEIEyIaMkUNJTATNMa5W6ddKYjWo8KIk1YlasMFzUyfl0mGfPIFhBRcWt68fYj-KpourkdKqGGCYG7naozOTvoxhphiDulwK-tV-qZSZsqts6EQsKm72ApNuLT7JetyDfRkY4uBr_yjwk69i58jfNEamNh-_mGIDLODkpDPIL7t3p0w priority: 102 providerName: Scholars Portal |
Title | Apolipoprotein B100 quality control and the regulation of hepatic very low density lipoprotein secretion |
URI | http://lib.cqvip.com/qk/85389A/201403/50318367.html https://www.ncbi.nlm.nih.gov/pubmed/25013401 https://search.proquest.com/docview/1544742970 https://pubmed.ncbi.nlm.nih.gov/PMC4085555 |
Volume | 28 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB6yObS9lL6zaRtU6KEX79prPaxjEhpCYEspDeRmZD26C4m8TTaUXPrbOyPby257qw8GI48tNGPNjPXpG4CPxuWucoJnUjdlxj2XWeNClcnGBptThZG0Q27-RZ5f8osrcbUHYtgLk0D7tllO4vXNJC4XCVu5urHTASc2_To_JVYuPKYjGKH73UrR0_RbajlLVbMIYJ9VaMEdpY8ikYuTb5NZgnRxim6IC1hgFMSpKMxjnHDij5_oMnad1D-R598Ayi2PdPYMnvahJDvuuvwc9nx8AY_m_WL5S1gcUwWGVZuoGJaRnRR5zrpNlA-sh6gzEx3DGJDddjXpUUusDWzhCWhtGdr5A7tufzFHOHcU237eHUWcJPEKLs8-fz89z_rCCpnllVhnOrdBSlM4ckYmBCG8K5TzJjeVCMrnZRCNarxSTmqLSbItjFYFXmAywkNRvob92EZ_AIz4SLVQZqYw0xRKV01pdGFK4YVzxuZjONyMar3qCDRqkWYSqcbwaRjmTRsmJaSoGhVVz6p6UNQYPgxqqPEDoFUNE317f1cTnRDm91rhu950atk8bNDtGNSOwjY3ELn2bgvaXCLZ7m3s8L8l38IT6nz3u-Yd7K9v7_17DGDWzRGMJr8LPM95dZSM9w9BjfGB |
link.rule.ids | 230,314,727,780,784,885,2221,24318,27924,27925,53791,53793 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9swDCa6Dlh3KfZeupcG7LCLEzu2JOvYFiuyrimGoQV6M2Q9mgCtnLUpiv77kbIdJNttvhkyZVukRdL69BHgi7apLS0vEqHqPClcIZLa-jIRtfEmpQojcYfc9FRMzovjC36xBbzfCxNB-6aeD8PV9TDMZxFbubg2ox4nNvo5PSRWLjxGj-Axz6XK1pL0OAHnSoxj3SyC2Ccl2nBL6iNJ6Pjg13AcQV0FxTfEBswxDiqoLMwOTjnh8jc6jU039U_s-TeEcs0nHT2D3S6YZPvtQz-HLRdewJNpt1z-Emb7VINh0UQyhnlgB1masnYb5QPrQOpMB8swCmQ3bVV61BNrPJs5globhpb-wK6ae2YJ6Y5i6_3dUsxJEq_g_Ojb2eEk6UorJKYo-TJRqfFC6MySO9Lec-5sJq3TqS65ly7NPa9l7aS0QhlMk02mlczwBNORwmf5a9gOTXBvgREjqeJSjyXmmlyqss61ynTOHbdWm3QAe6tRrRYthUbF41wi5AC-9sO8asO0hBRVoaKqcVn1ihrA514NFX4CtK6hg2vubisiFMIMX0m815tWLavOet0OQG4obHUB0WtvtqDVRZrtzsr2_lvyE-xMzqYn1cn30x_v4Cm9SPvz5j1sL2_u3AcMZ5b1x2i8fwDAIPL- |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5BkQoXVN5bKBiJA5fsJpvYjo99rUphqwpRqbfI8YNdqXWWdivUf8-Mk6x24UZukTNO4pl4ZuLP3wB80ja1peVFIlSdJ4UrRFJbXyaiNt6kVGEk7pCbnomTi-L0kl-ulfqKoH1Tz4fh6noY5rOIrVxcm1GPExudTw-JlQuP0cL60UN4xHM0srVEPU7CuRLjWDuLYPZJiXbcEvtIEjw9-D4cR2BXQTEOMQJzjIUKKg3zGKed8PMXOo5NV_VP_Pk3jHLNL0124GkXULL99sGfwQMXnsP2tFsyfwGzfarDsGgiIcM8sIMsTVm7lfKedUB1poNlGAmym7YyPeqKNZ7NHMGtDUNrv2dXzW9mCe2OYuv93VLcSRIv4WJy_OPwJOnKKySmKPkyUanxQujMkkvS3nPubCat06kuuZcuzT2vZe2ktEIZTJVNppXM8ARTksJn-SvYCk1wb4ARK6niUo8l5ptcqrLOtcp0zh23Vpt0ALurUa0WLY1GxeN8IuQAPvfDvGrD1IQUVaGiqnFZ9YoawMdeDRV-BrS2oYNr7m4rIhXCLF9JvNfrVi2rznrdDkBuKGx1AVFsb7ag5UWq7c7Sdv9b8gNsnx9Nqm9fzr6-hSf0Hu3_m3ewtby5c3sY0Szr99F2_wBH4vQR |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Apolipoprotein+B100+quality+control+and+the+regulation+of+hepatic+very+low+density+lipoprotein+secretion&rft.jtitle=Journal+of+biomedical+research&rft.au=Fisher%2C+Eric&rft.au=Lake%2C+Elizabeth&rft.au=McLeod%2C+Roger+S&rft.date=2014-01-01&rft.issn=1674-8301&rft.volume=28&rft.issue=3&rft.spage=178&rft_id=info:doi/10.7555%2Fjbr.28.20140019&rft_id=info%3Apmid%2F25013401&rft.externalDocID=25013401 |
thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F85389A%2F85389A.jpg |